title: U.S. Wingspan Registry: 12-month follow-up results.
abstract: OBJECTIVE
  The purpose of this study is to present 12-month follow-up results for a series of patients undergoing percutaneous transluminal angioplasty and stenting with the Gateway-Wingspan stenting system (Boston Scientific) for the treatment of symptomatic intracranial atherostenosis.
  
  
  METHODS
  Clinical and angiographic follow-up results were recorded for patients from 5 participating institutions. Primary end points were stroke or death within 30 days of the stenting procedure or ipsilateral stroke after 30 days.
  
  
  RESULTS
  During a 21-month study period, 158 patients with 168 intracranial atherostenotic lesions (50% to 99%) were treated with the Gateway-Wingspan system. The average follow-up duration was 14.2 months with 143 patients having at least 3 months of clinical follow-up and 110 having at least 12 months. The cumulative rate of the primary end point was 15.7% for all patients and 13.9% for patients with high-grade (70% to 99%) stenosis. Of 13 ipsilateral strokes occurring after 30 days, 3 resulted in death. Of these strokes, 76.9% (10 of 13) occurred within the first 6 months of the stenting procedure and no events were recorded after 12 months. An additional 9 patients experienced ipsilateral transient ischemic attack after 30 days. Most postprocedural events (86%) could be attributed to interruption of antiplatelet medications (n=6), in-stent restenosis (n=12), or both (n=1). In 3 patients, the events were of uncertain etiology.
  
  
  CONCLUSIONS
  After successful Wingspan percutaneous transluminal angioplasty and stenting, some patients continued to experience ipsilateral ischemic events. Most of these ischemic events occurred within 6 months of the procedure and were associated with the interruption of antiplatelet therapy or in-stent restenosis.
authors.affiliation: Stony Brook University Medical Center, Department of Neurological Surgery, Health Sciences Center T-12 080, Stony Brook, NY 11794, USA. dfiorella@notes.cc.sunysb.edu
authors.forename: David J
authors.initials: DJ
authors.lastname: Fiorella
authors.forename: Aquilla S
authors.initials: AS
authors.lastname: Turk
authors.forename: Elad I
authors.initials: EI
authors.lastname: Levy
authors.forename: G Lee
authors.initials: GL
authors.lastname: Pride
authors.forename: Henry H
authors.initials: HH
authors.lastname: Woo
authors.forename: Felipe C
authors.initials: FC
authors.lastname: Albuquerque
authors.forename: Babu G
authors.initials: BG
authors.lastname: Welch
authors.forename: David B
authors.initials: DB
authors.lastname: Niemann
authors.forename: Beverly
authors.initials: B
authors.lastname: Aagaard-Kienitz
authors.forename: Peter A
authors.initials: PA
authors.lastname: Rasmussen
authors.forename: L Nelson
authors.initials: LN
authors.lastname: Hopkins
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Masaryk
authors.forename: Cameron G
authors.initials: CG
authors.lastname: McDougall
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017130:Angioplasty / Q000379:methods; D000800:Angioplasty, Balloon / Q000009:adverse effects / Q000379:methods*; D002548:Cerebral Revascularization / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012042:Registries; D015607:Stents; D016896:Treatment Outcome; D014481:United States